163 related articles for article (PubMed ID: 34971582)
1. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials.
Kahn JM; Pei Q; Friedman DL; Kaplan J; Keller FG; Hodgson D; Wu Y; Appel BE; Bhatia S; Henderson TO; Schwartz CL; Kelly KM; Castellino SM
Lancet Haematol; 2022 Jan; 9(1):e49-e57. PubMed ID: 34971582
[TBL] [Abstract][Full Text] [Related]
2. Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children's Oncology Group Study.
Kahn JM; Kelly KM; Pei Q; Bush R; Friedman DL; Keller FG; Bhatia S; Henderson TO; Schwartz CL; Castellino SM
J Clin Oncol; 2019 Nov; 37(32):3009-3017. PubMed ID: 31539308
[TBL] [Abstract][Full Text] [Related]
3. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.
Miller TP; Getz KD; Li Y; Demissei BG; Adamson PC; Alonzo TA; Burrows E; Cao L; Castellino SM; Daves MH; Fisher BT; Gerbing R; Grundmeier RW; Krause EM; Lee J; Lupo PJ; Rabin KR; Ramos M; Scheurer ME; Wilkes JJ; Winestone LE; Hawkins DS; Gramatges MM; Aplenc R
Lancet Haematol; 2022 Sep; 9(9):e678-e688. PubMed ID: 35870472
[TBL] [Abstract][Full Text] [Related]
4. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group.
Keller FG; Castellino SM; Chen L; Pei Q; Voss SD; McCarten KM; Senn SL; Buxton AB; Bush R; Constine LS; Schwartz CL
Cancer; 2018 Aug; 124(15):3210-3219. PubMed ID: 29738613
[TBL] [Abstract][Full Text] [Related]
5. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials.
Gupta S; Dai Y; Chen Z; Winestone LE; Teachey DT; Bona K; Aplenc R; Rabin KR; Zweidler-McKay P; Carroll AJ; Heerema NA; Gastier-Foster J; Borowitz MJ; Wood BL; Maloney KW; Mattano LA; Larsen EC; Angiolillo AL; Burke MJ; Salzer WL; Winter SS; Brown PA; Guest EM; Dunsmore KP; Kairalla JA; Winick NJ; Carroll WL; Raetz EA; Hunger SP; Loh ML; Devidas M
Lancet Haematol; 2023 Feb; 10(2):e129-e141. PubMed ID: 36725118
[TBL] [Abstract][Full Text] [Related]
6. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL; Million L; Chi YY; Anderson J; Tian J; Hibbitts E; Coffin C; McCarville MB; Randall RL; Parham DM; Black JO; Kao SC; Hayes-Jordan A; Wolden S; Laurie F; Speights R; Kawashima E; Skapek SX; Meyer W; Pappo AS; Hawkins DS
Lancet Oncol; 2020 Jan; 21(1):145-161. PubMed ID: 31786124
[TBL] [Abstract][Full Text] [Related]
7. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.
Yang W; Cai J; Shen S; Gao J; Yu J; Hu S; Jiang H; Fang Y; Liang C; Ju X; Wu X; Zhai X; Tian X; Wang N; Liu A; Jiang H; Jin R; Sun L; Yang M; Leung AWK; Pan K; Zhang Y; Chen J; Zhu Y; Zhang H; Li C; Yang JJ; Cheng C; Li CK; Tang J; Zhu X; Pui CH
Lancet Oncol; 2021 Sep; 22(9):1322-1332. PubMed ID: 34329606
[TBL] [Abstract][Full Text] [Related]
8. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study.
Bhakta N; Liu Q; Yeo F; Baassiri M; Ehrhardt MJ; Srivastava DK; Metzger ML; Krasin MJ; Ness KK; Hudson MM; Yasui Y; Robison LL
Lancet Oncol; 2016 Sep; 17(9):1325-34. PubMed ID: 27470081
[TBL] [Abstract][Full Text] [Related]
9. Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study.
Ferrari A; Chisholm JC; Jenney M; Minard-Colin V; Orbach D; Casanova M; Guillen G; Glosli H; van Rijn RR; Schoot RA; Cameron AL; Rogers T; Alaggio R; Ben-Arush M; Mandeville HC; Devalck C; Defachelles AS; Coppadoro B; Bisogno G; Merks JHM
Lancet Child Adolesc Health; 2022 Aug; 6(8):545-554. PubMed ID: 35690071
[TBL] [Abstract][Full Text] [Related]
10. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
von Tresckow B; Kreissl S; Goergen H; Bröckelmann PJ; Pabst T; Fridrik M; Rummel M; Jung W; Thiemer J; Sasse S; Bürkle C; Baues C; Diehl V; Engert A; Borchmann P;
Lancet Haematol; 2018 Oct; 5(10):e462-e473. PubMed ID: 30290903
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
12. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group.
Kelly KM; Cole PD; Pei Q; Bush R; Roberts KB; Hodgson DC; McCarten KM; Cho SY; Schwartz C
Br J Haematol; 2019 Oct; 187(1):39-48. PubMed ID: 31180135
[TBL] [Abstract][Full Text] [Related]
13. Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study.
Maggen C; Dierickx D; Lugtenburg P; Laenen A; Cardonick E; Shmakov RG; Bellido M; Cabrera-Garcia A; Gziri MM; Halaska MJ; Ottevanger PB; Van Calsteren K; O'Laughlin A; Polushkina E; Van Dam L; Avivi I; Vandenberghe P; Woei-A-Jin FJSH; Amant F;
Lancet Haematol; 2019 Nov; 6(11):e551-e561. PubMed ID: 31564649
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J
Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680
[TBL] [Abstract][Full Text] [Related]
16. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
[TBL] [Abstract][Full Text] [Related]
17. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
Casasnovas RO; Bouabdallah R; Brice P; Lazarovici J; Ghesquieres H; Stamatoullas A; Dupuis J; Gac AC; Gastinne T; Joly B; Bouabdallah K; Nicolas-Virelizier E; Feugier P; Morschhauser F; Delarue R; Farhat H; Quittet P; Berriolo-Riedinger A; Tempescul A; Edeline V; Maisonneuve H; Fornecker LM; Lamy T; Delmer A; Dartigues P; Martin L; André M; Mounier N; Traverse-Glehen A; Meignan M
Lancet Oncol; 2019 Feb; 20(2):202-215. PubMed ID: 30658935
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
19. Therapy results in pediatric Hodgkin lymphoma - does less mean better? Experience from a single children's oncology center.
Stankiewicz J; Kołtan A; Demidowicz E; Bartoszewicz N; Kołtan S; Czyżewski K; Richert-Przygońska M; Dębski R; Pogorzała M; Tejza B; Cisek J; Księżniakiewicz P; Jatczak-Gaca A; Marjańska A; Salamon M; Dąbrowska A; Urbańczyk A; Grześk E; Jaremek K; Łęcka M; Grochowska O; Styczyński J
Ann Hematol; 2023 Aug; 102(8):2109-2117. PubMed ID: 37195291
[TBL] [Abstract][Full Text] [Related]
20. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children.
Lo AC; Liu A; Liu Q; Yasui Y; Castellino SM; Kelly KM; Hererra AF; Friedberg JW; Friedman DL; Schwartz CL; Pei Q; Kessel S; Bergeron-Gravel S; Dama H; Roberts K; Constine LS; Hodgson DC
JAMA Netw Open; 2024 Jan; 7(1):e2351062. PubMed ID: 38241048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]